Key Highlights

  • Upon closing, Dr. Conrad Ivie is expected to own approximately 80% of PCMC’s outstanding Common Stock and will be appointed CEO.
  • The agreement includes significant governance changes, including a restructured board and new executive leadership.

Approved on June 30, 2026, this transaction is designed to reposition PCMC within its sector by integrating new leadership and strategic direction.

Deal Structure Overview

Under the terms of the agreement, Dr. Conrad Ivie, the sole shareholder of Physicians Capital Management, will transfer ownership of his company’s shares in exchange for a substantial equity stake in PCMC. Once the transaction is completed, these shares will account for approximately 80% of PCMC’s total outstanding equity, consolidating Ivie’s control over the company.

Share Breakdown

The Preferred Stock issued in this transaction is structured to include distinct classes with varying rights. The Series A shares carry voting rights, whereas the convertible shares, totaling 15,942,612 and 7,971,306, may be exchanged for Common Stock following defined holding periods. This tiered structure allows for flexibility in future capital management and investor engagement.

Governance Changes

The closing of this transaction will trigger significant changes in PCMC’s leadership and governance. Dr. Ivie is slated to assume the role of Chief Executive Officer, replacing the existing management team.

Additionally, the Board of Directors will undergo a restructuring to reflect Ivie’s majority ownership, ensuring alignment between leadership and shareholder interests. These changes are expected to drive a renewed strategic focus for the company as it transitions out of its current status.

Future Capital Structure

Following the transaction, PCMC’s authorized capital will consist of 500,000,000 shares of Common Stock and 50,000,000 shares of Preferred Stock, both with a par value of $0.001 per share. This expanded capital framework is intended to support the company’s growth objectives and provide additional financing options as it evolves.

Regulatory Considerations

The completion of this share exchange is subject to customary closing conditions, including regulatory approvals and compliance with federal securities laws. As the company currently operates as a "shell company" under Rule 12b, this transaction marks a critical step toward operational expansion and regulatory compliance.

Timeline and Expectations

The closing of the share exchange is targeted for the third quarter of 2026, pending the fulfillment of all regulatory and legal requirements. Once finalized, the transaction is expected to reshape PCMC’s market positioning, with Dr. Ivie’s leadership driving new strategic initiatives.

The deal reflects a broader trend in the sector, where companies leverage share exchanges to accelerate growth and enhance shareholder value.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.